AAAAAA

   
Results: 1-14 |
Results: 14
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408
Authors: Miller, MD Margot, NA Lamy, PD Fuller, MD Anton, KE Mulato, AS Cherrington, JM
Citation: Md. Miller et al., Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408, J ACQ IMM D, 27(5), 2001, pp. 450-458
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit theSCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
Authors: Smolich, BD Yuen, HA West, KA Giles, FJ Albitar, M Cherrington, JM
Citation: Bd. Smolich et al., The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit theSCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts, BLOOD, 97(5), 2001, pp. 1413-1421
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts
Authors: Strawn, LM Kabbinavar, F Schwartz, DP Mann, E Shawver, LK Slamon, DJ Cherrington, JM
Citation: Lm. Strawn et al., Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts, CLIN CANC R, 6(7), 2000, pp. 2931-2940
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
Authors: Mendel, DB Schreck, RE West, DC Li, GM Strawn, LM Tanciongco, SS Vasile, S Shawver, LK Cherrington, JM
Citation: Db. Mendel et al., The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function, CLIN CANC R, 6(12), 2000, pp. 4848-4858
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
Authors: Mendel, DB Laird, AD Smolich, BD Blake, RA Liang, CX Hannah, AL Shaheen, RM Ellis, LM Weitman, S Shawver, LK Cherrington, JM
Citation: Db. Mendel et al., Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent, ANTI-CAN DR, 15(1), 2000, pp. 29-41
New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
Authors: Cherrington, JM Strawn, LM Shawver, LK
Citation: Jm. Cherrington et al., New paradigms for the treatment of cancer: The role of anti-angiogenesis agents, ADV CANC R, 79, 2000, pp. 1-38
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA
Authors: Van Rompay, KKA Miller, MD Marthas, ML Margot, NA Dailey, PJ Canfield, DR Tarara, RP Cherrington, JM Aguirre, NL Bischofberger, N Pedersen, NC
Citation: Kka. Van Rompay et al., Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA, J VIROLOGY, 74(4), 2000, pp. 1767-1774
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
Authors: Laird, AD Vajkoczy, P Shawver, LK Thurnher, A Liang, C Mohammadi, M Schlessinger, J Ullrich, A Hubbard, SR Blake, RA Fong, TAT Strawn, LM Sun, L Tang, C Hawtin, R Tang, F Shenoy, N Hirth, KP McMahon, G Cherrington, JM
Citation: Ad. Laird et al., SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors, CANCER RES, 60(15), 2000, pp. 4152-4160
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA
Authors: Wainberg, MA Miller, MD Quan, YD Salomon, H Mulato, AS Lamy, PD Margot, NA Anton, KE Cherrington, JM
Citation: Ma. Wainberg et al., In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA, ANTIVIR TH, 4(2), 1999, pp. 87-94
Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy
Authors: Bowen, EF Cherrington, JM Lamy, PD Griffiths, PD Johnson, MA Emery, VC
Citation: Ef. Bowen et al., Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy, J MED VIROL, 58(4), 1999, pp. 402-407
9-[2-(phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA
Authors: Van Rompay, KKA Cherrington, JM Marthas, ML Lamy, PD Dailey, PJ Canfield, DR Tarara, RP Bischofberger, N Pedersen, NC
Citation: Kka. Van Rompay et al., 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA, ANTIM AG CH, 43(4), 1999, pp. 802-812
Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques
Authors: Van Rompay, KKA Dailey, PJ Tarara, RP Canfield, DR Aguirre, NL Cherrington, JM Lamy, PD Bischofberger, N Pedersen, NC Marthas, ML
Citation: Kka. Van Rompay et al., Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques, J VIROLOGY, 73(4), 1999, pp. 2947-2955
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
Authors: Miller, MD Anton, KE Mulato, AS Lamy, PD Cherrington, JM
Citation: Md. Miller et al., Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro, J INFEC DIS, 179(1), 1999, pp. 92-100
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: Relationship to clinical outcome
Authors: Cherrington, JM Fuller, MD Lamy, PD Miner, R Lalezari, JP Nuessle, S Drew, WL
Citation: Jm. Cherrington et al., In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: Relationship to clinical outcome, J INFEC DIS, 178(6), 1998, pp. 1821-1825
Risultati: 1-14 |